Core Insights - Prestige Consumer Healthcare Inc. has expanded the role of Chief Financial Officer Christine Sacco to include Chief Operating Officer responsibilities, effective immediately [1][2] - This strategic move aims to enhance execution of the company's initiatives and drive operational excellence [2] Group 1: Leadership Changes - Christine Sacco has been appointed as both COO and CFO, overseeing the supply chain in addition to her financial responsibilities [1] - Ron Lombardi, CEO of Prestige, emphasized Sacco's strategic leadership and understanding of the business as key to the company's growth during her 8 years as CFO [2] Group 2: Company Performance - Under Sacco's financial leadership since 2016, the company has experienced strong sales, earnings, and cash flow growth, positioning it for future capital allocation flexibility [2] - The company is focused on driving long-term organic and M&A growth through this expanded leadership role [2] Group 3: Company Overview - Prestige Consumer Healthcare is a leading consumer healthcare products company with a diverse portfolio including brands like Monistat, BC, and Dramamine, with sales across the U.S., Canada, Australia, and other international markets [3]

Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and es ...

Prestige Consumer Healthcare’s (PBH) dedication to brand building drives consistent market share growth. The company has grown its portfolio through internal developments and strategic acquisitions. Investments in online content and digital advertising fuel the company’s e-commerce success. Meanwhile, cost pressures from macroeconomic headwinds and solvency issues weigh on Prestige Consumer’s operations.In the past year, this Zacks Rank #2 (Buy) stock has rallied 27.2% compared with the industry and the S&P ...

Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Abbott (ABT) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings es ...

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medicine distributor would post earnings of $0.86 per share when it actually produced earnings of $0.90, delivering a surprise of 4.65%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Prestig ...

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our S ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the s ...

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highl ...

TARRYTOWN, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 first quarter earnings release on Thursday, August 8, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate ...

Prestige Consumer Healthcare Inc. (PBH) delivered fourth-quarter fiscal 2024 earnings per share (EPS) of $1.02, a 4.7% decline from the year-ago period's figure. The metric also missed the Zacks Consensus Estimate by 10.5%. GAAP EPS for the quarter was 98 cents, a significant improvement from the year-ago loss of $4.78 per share. For the full year, adjusted EPS was $4.21, flat year over year. Revenues Total revenues in the fiscal fourth quarter declined 3.1% year over year (down 2.9% on an organic basis) to ...